New drug combo tested to keep ovarian cancer at bay
NCT ID NCT07370818
Summary
This study is testing a new drug combination, JPI-547 with bevacizumab, as a maintenance therapy for women with recurrent ovarian cancer. It aims to see if this combination can help keep the cancer from progressing after patients have responded to platinum-based chemotherapy. The study will enroll 81 participants to find the right dose and see how well it works compared to standard care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Severance Hospital, Yonsei Cancer Center, Yonsei University College of Medicine
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.